Bayer AG, DE000BAY0017

Bayer stock holds near a 2026 high after Q2 revenue of €10.74 billion

Published on 08/14/2026 at 16:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock is consolidating near the high-€40s after Q2 2026 revenue reached €10.74 billion and adjusted EBITDA came in at €2.14 billion.

Aquarellbild einer Industriestadt-Skyline am Flussufer mit sanften Farbverläufen
Bayer AG (DE000BAY0017): Aquarellmalerei der Skyline von Leverkusen mit Industrieanlagen am Rhein, Illustration mit AI erstellt.

Bayer stock (DE000BAY0017) held near the high-€40s on August 14, 2026, after a recent quote snapshot showed €48.06 and a market value of €48.52 billion. The same snapshot put the shares 29.9% above the start of 2026 level and close to the 52-week range top of €53.36.

Q2 figures still set the tone

A recent earnings summary said second-quarter 2026 revenue reached €10.74 billion and adjusted EBITDA was €2.14 billion. It also pointed to a mean analyst view of outperform with 18 analysts and an average target price of €56.81, which leaves the shares below that reference level.

The comparison is important for investors because the stock is still trading below the cited target while operating figures remain anchored to the latest quarter. That keeps the discussion centered on execution rather than on a one-day headline move.

Trading range matters

Market data from August 14, 2026 also showed a 50-day range from €35.37 to €53.36 and volume of 1.60 million shares. The price sat 9.26% below the 52-week high cited in the same market snapshot, which is a measurable gap after the year-to-date advance.

That kind of setup usually pushes attention toward whether the recent quarter can support the valuation band around €50. For Bayer, the next move is less about one quote and more about whether the latest operating trend can hold.

Crop protection remains central

One representative product area is crop protection, where the company sells herbicides, fungicides and insecticides to farmers and distributors worldwide. That segment matters because it feeds both revenue scale and margin stability in a business that also carries pharmaceuticals and consumer health.

Shares stay in range

The shares were last quoted at €48.06 on August 13, 2026, with a market capitalization of €48.52 billion and a year-to-date gain of 29.9%. For Bayer stock, the key reference point remains the gap between that trading level and the €56.81 average target cited in recent market data.

Fact box

Company: Bayer AG

ISIN: DE000BAY0017

Ticker: BAYN

Exchange: Xetra

Price (as of August 13, 2026): €48.06

Market cap: €48.52 billion

Sector / Industry: Health Care / Pharmaceuticals

Index membership: DAX

Next earnings date: November 4, 2026

More on Bayer stock

More on Bayer stock. The main watchpoint is whether the current valuation can stay supported by the latest quarterly numbers and the market's €56.81 consensus target.

Disclaimer...

en | DE000BAY0017 | BAYER AG | boerse | 69949763 | bgmi